Osteopore, NDCS and A*STAR project hits key milestones 

Australian-Singaporean regenerative medicine company Osteopore has shared the exciting progress made by its clinical-industrial partnership with the National Dental Centre Singapore (NDCS) and the Agency for Science, Technology and Research (A*STAR).

On 13 December 2021, Osteopore announced the signing of an agreement with NDCS and A*STAR to launch a US$12.4m (A$18.7m) dental implant project. The project’s key milestones included combining patented biological additives and polymer compounds to test for adverse reactions, osteogenic differentiation to indicate bone growth, and higher osteogenic differentiation to demonstrate faster bone growth.

Osteopore
(Image: Osteopore)

Osteopore has announced the successful development of a 3D-printed technology, which can combine patented biological additives and polymer compounds for dental implants that have the potential to accelerate bone healing.

Adverse reaction testing demonstrated that the successful combination of patented biological additives and polymer compounds was non-cytotoxic, showing no adverse reactions and good biocompatibility.

Moreover, osteogenic differentiation testing showed enhanced viability and osteogenic differentiation capabilities, indicating both osteogenic differentiation and higher osteogenic differentiation. The next-generation dental implant project is now set to progress towards in vivo studies in biological models.

“We are excited by the outcomes of this project so far and appreciate the support of our partners at A*STAR and NDCS. We are delighted with the dedication of our partners towards ensuring that project milestones are met,” said Dr Yujing Lim, CEO of Osteopore.

“While we continue to prioritise our objective of commercialising our current products, we are looking forward to working on new technologies – such as the next-generation jaw implant – which supports our long-term vision of becoming the global leader in regenerative medicine.”

The global dental bone graft and membrane substitutes market was valued at USD$11.47 billion in 2023, with a projected value of USD$27.55 billion by 2030,1 according to Verified Market Reports.

Osteopore commercialises products designed to enable natural bone healing across multiple therapeutic areas. Its patented technology fabricates specific micro structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

References

  1. https://www.verifiedmarketreports.com/product/dental-membrane-and-bone-graft-substitutes-market-size and-forecast/

Related: Osteopore and SingHealth partner on Global Centre of Excellence